|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
PERSPECTIVEImplantable Cardioverter Defibrillators: An Excellent Case StudyNumerous randomized controlled trials have shown that implantable cardioverter defibrillators (ICDs) reduce mortality from sudden cardiac death. Evidence-based medicine can elucidate the benefits of treatment and inform Medicare policy when applied in a consistent and nonselective manner. The use of cost-effectiveness data to determine Medicare coverageand therefore access to a therapyinvolves many practical challenges. Cost-effectiveness analysis may be more useful as a tool to guide marketplace decision making than as a regulatory mechanism. Medicare coverage does not mandate use of a therapy; it allows the discussion to occur between a patient and his or her doctor.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||